Close Banner
Section Free  - Video Lectures

03. Managing Clozapine-Induced Constipation: Practical Advice

Published on April 1, 2018 Expired on March 31, 2022

Jonathan M. Meyer, M.D.

Assistant Clinical Professor - University of California San Diego

Key Points

  • Bulk agents can make constipation worse and should be avoided
  • After docusate, the next agent to add is PEG-3350, and if needed a stimulant (and lastly) lubiprostone

Free Downloads for Offline Access

  • Free Download Video (MP4)
  • Free Download Audio File (MP3)
  • Free Download Presentation File (PPTX)

Transcript

 

 

 

 

 

References

  1. Hesketh PJ. N Engl J Med 2008 358: 2482-2494.
  2. Nielsen J and Meyer JM. Risk factors for ileus in patients with schizophrenia . Schizophrenia Bulletin 2010, 1-7
  3. Nielsen J and Meyer JM. Risk factors for ileus in patients with schizophrenia . Schiz Bull 2012; 38(3):592-8
  4. Meyer JM, Cummings MA. Lubiprostone for treatment-resistant constipation associated with clozapine use . Acta Psych Scand 2014; 130(1): 71-72.p
  5. American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Constipation . American Journal of Gastroenterology 2014; 109: S2-S26.

 

Next Section

04. Managing Orthostasis

Earn credits for your learning!

No CMEs available

Certification expiration date: March 31, 2022

CME Information

Learning Objectives:

After completing this activity, the learner will be able to:

  1. Identify common adverse effects of clozapine
  2. Implement management strategies for adverse effects of clozapine

Original Release Date: 04/01/2018

Expiration Date: 03/31/2022

Relevant Financial Disclosures: 

The following planners, faculty, and reviewers have the following relevant financial relationships with commercial interests to disclose:

Dr. Meyer has disclosed the following relationships:

  • Acadia: Advisory committee, speaking
  • Allergan: Advisory committee, speaking
  • Alkermes: Advisory committee, speaking
  • Intra-Cellular Therapies: Advisory committee
  • Janssen Pharmaceutica: Speaking
  • Merck: Speaking
  • Neurocrine: Advisory committee, speaking
  • Otsuka America, Inc.: Speaking
  • Sunovion Pharmaceuticals: Speaking
  • Acadia: Advisory board, speaking
  • Allergan: Advisory board, speaking
  • Alkermes: Advisory board, speaking
  • Intra-cellular: Advisory board
  • Janssen: Speaking
  • Impel: Advisory board
  • Otsuka: Speaking
  • Neurocrine: Advisory board, speaking
  • Sunovion: Speaking

All of the relevant financial relationships listed for these individuals have been mitigated.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Free Files

Free Downloads for Offline Access

Success!
Check your inbox, we sent you all the materials there.
Continue in the website
Instant access modal

Become a Bronze, Silver, Gold, Bronze extended, Silver extended or Gold extended Member.

2025–26 Psychopharmacology CME Program

Unlock up to 155 CME Credits, including 40 SA CME Credits.

Get Instant Access
Or login if you have an account